Abstract: Diabetes mellitus is a leading reason for morbidity and death worldwide, with an approximated 346 million grownups being impacted in year 2011. The occurrence is anticipated to double in between years 2005 and 2030. A systematic review of published studies reporting the effects of melatonin on diabetes mellitus was undertaken in accordance with the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) statement for systematic reviews of interventional studies. A three staged comprehensive search of the literature was conducted in the following databases; PubMed (U.S. National Library of Medicine, USA), and SciVerse Scopus (Elsevier Properties S.A, USA) for studies published before October 2016. The data discussed in this review shed new light on melatonin as a hormone which acts on diverse physiological processes in mammals and, particularly, on pancreatic islet functions. General agreement exists that the physical effects of melatonin are mediated through the activity of two known membrane receptor isoforms, MT1 and MT2, which belong to the large family of G-protein-coupled receptors. Numerous studies support the notion that activation of either receptor isoform leads to a reduction in second messenger cAMP or, in the case of the MT2, also to cGMP levels, due to a coupling of the receptor with G-proteins which inhibit AC activity.
Keywords: Diabetes mellitus, melatonin.
Title: Role of melatonin in Diabetes mellitus, Systemic review
Author: Khaled S.S Shabrawy, Duaa Jihad Zain Basrawi, Rasha Shaker Alkhunizi, Saleh Abdulaziz Alghamdi, Salman Abdulrahman Alolait
International Journal of Healthcare Sciences
ISSN 2348-5728 (Online)
Research Publish Journals
